Browse evidence-based analysis of health-related claims and assertions
In HIV patients on placebo, losing visceral fat didn't lead to lower liver enzymes, unlike those taking tesamorelin.
HIV patients with high ALT who lost visceral fat had a 35% chance of normalizing their ALT levels after 6 months, compared to 18% who didn't lose fat, showing a clear benefit.
Whether HIV patients had hepatitis or not didn't change the benefit of visceral fat loss on liver enzymes when taking tesamorelin.
In HIV patients with belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels at the start of the study.
Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.
HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.
HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.
Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.
Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.
Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.
For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.
For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.
In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin did not show a significant improvement in thinking skills compared to those who received usual care after six months. This finding is from the abstract summary - full study details were not available
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available
Stopping tesamorelin causes the positive effects to go away in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available
Taking tesamorelin makes people with HIV feel better about their belly appearance. This finding is from the abstract summary - full study details were not available
Tesamorelin helps lower blood fat levels in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available
Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available
Taking tesamorelin is linked to less belly fat in people with HIV who have body shape changes. This finding is from the abstract summary - full study details were not available
Adding omentum removal to gastric bypass surgery didn't change levels of hormones produced by fat tissue (adipokines) in women with severe obesity and metabolic syndrome.
Non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery with omentum removal had better overall insulin function (disposition index) at 6 and 12 months compared to those who only had the bypass.
For non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery, adding omentum removal helped maintain their body's insulin response to sugar after one year, while those without it saw a decline.